November 15, 2022
2 min watch
Save
VIDEO: Myeloproliferative neoplasms treatment may be ‘driven by genomic distinctions’
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
John O. Mascarenhas, MD, spoke with Healio about a presentation given during the morning session at 14th International Congress on Myeloproliferative Neoplasms.
“Ann Mullally gave a terrific talk about mutant calreticulin,” Mascarenhas, professor of medicine at Icahn School of Medicine at Mount Sinai, director of Center of Excellence for Blood Cancer and Myeloid Disorders, and member of Tisch Cancer Institute, said. “I think we’re going to see the field move in different directions and it will be, in large part, driven by genomic distinctions within the diseases.”
References:
- Moliterno A. JAK2V617F VAF: clinical significance and applications. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
- Mullally A. Pursuing monoclonal antibodies for MPNS: targeting mutant calreticulin. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
- Prchal JT. Oxygen-sensing mechanisms and erythrocytosis. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
- Scandura JM. Are megakarocytes the root of MPN evils? Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mascarenhas reports serving as a consultant for AbbVie, Bristol Myers Squibb, Celgene, Constellation, CTI Biopharma, Galecto, Geron, GSK, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia, Roche and Sierra Oncology; and receiving funding paid to his institution from AbbVie, Bristol Myers Squibb, Celgene, CTI Biopharma, Geron, Incyte, Kartos, Merck, Novartis, PharmaEssentia and Roche.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.